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Immunoglobulins are unique molecules capable of simultaneously recognizing a diverse
array of antigens and themselves being recognized by a broad array of receptors. The
abundance speciﬁcally of the IgG subclass and the variety of signaling receptors to which
it binds render this an important immunomodulatory molecule. In addition to the clas-
sical Fcg receptors that bind IgG at the cell surface, the neonatal Fc receptor (FcRn)
is a lifelong resident of the endolysosomal system of most hematopoietic cells where
it determines the intracellular fate of both IgG and IgG-containing immune complexes
(IgG IC). Cross-linking of FcRn by multivalent IgG IC within antigen presenting cells such
as dendritic cells initiates speciﬁc mechanisms that result in trafﬁcking of the antigen-
bearing IgG IC into compartments from which the antigen can successfully be processed
into peptide epitopes compatible with loading onto both major histocompatibility com-
plex class I and II molecules. In turn, this enables the synchronous activation of both
CD4C and CD8C T cell responses against the cognate antigen, thereby bridging the gap
between the humoral and cellular branches of the adaptive immune response. Critically,
FcRn-driven T cell priming is efﬁcient at very low doses of antigen due to the exquis-
ite sensitivity of the IgG-mediated antigen delivery system through which it operates.
FcRn-mediated antigen presentation has important consequences in tissue compartments
replete with IgG and serves not only to determine homeostatic immune activation at a
variety of sites but also to induce inﬂammatory responses upon exposure to antigens
perceived as foreign. Therapeutically targeting the pathway by which FcRn enables T
cell activation in response to IgG IC is thus a highly attractive prospect not only for the
treatment of diseases that are driven by immune complexes but also for manipulating
local immune responses against deﬁned antigens such as those present during infections
and cancer.
Keywords: FcRn, IgG, antigen presentation, dendritic cells, immune complex
INTRODUCTION
Coordination of immune responses is of key importance to
the maintenance of homeostasis within multicellular organisms.
Fundamental to this process is the recognition, processing, and
presentation of antigenic agents that allows integration of the var-
ious branches of the innate and adaptive immune systems that
cooperate to confer maximal protective immunity.Antigen detec-
tion, which serves as the initiating event in this cascade, occurs
vianumerousmechanismshavingvaryinglevelsof sensitivityand
speciﬁcity. How an antigen is detected depends at once on the
nature of the antigen itself as well as on the particular immune
cell that detects it.Whereas small soluble antigens can be taken up
passively via macropinocytosis or ﬂuid phase endocytosis, larger
antigens require processes such as phagocytosis for cellular entry.
Speciﬁcityforantigendetection,uptake,and/orprocessingiscon-
ferred by cellular receptors that may bind to a unique ligand,
such as insulin-like growth factor receptor 1 (IGFR1), or to a
conserved motif present on many ligands, such as the mannose
receptor (MR) DC-SIGN. In each case, ligand binding by the
receptorcannotonlyinitiateligandinternalizationbutalsotrigger
additionalsignalingcascades,whichexertdirectorindirecteffects
on subsequent antigen presentation.
Recognition of IgG by Fcg receptors (FcgRs) represents an
important strategy that enables the delivery of unique antigenic
determinantsintheformof anIgGimmunecomplex(IgGIC)via
binding of the conserved Fc receptor (FcRn) domains on IgG to
their receptor. In antigen presenting cells (APCs), this process is
initiated at the cell surface by FcgR ligation, which triggers both
the internalization of IgG and its delivery into endocytic vesicles.
Importantly, while monomeric IgG is efﬁciently recycled from
these compartments to the cell surface, antigen-containing IgG
immune complexes (IgG IC) are instead trafﬁcked into vesicles
where processing of the complexed antigen releases epitopes that
areloadedontoMHCclassI(MHC-I)andclassII(MHC-II)mol-
eculesthatsubsequentlystimulatetheactivationof cognateCD8C
and CD4C T cells. Importantly,following entry into the cell,rout-
ing of the IgG or IgG IC through the maze of acidic endocytic
compartments is mediated neither by FcgR nor by non-speciﬁc
distributive mechanisms but rather by the speciﬁc binding of IgG
to its intracellular receptor,the neonatal Fc receptor (FcRn).
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Best known for its roles in protecting circulating IgG from
catabolism and mediating IgG transcytosis across polarized
epithelialcellsatmucosalsurfaces,FcRnalsoplaysacriticalrolein
theimmunesystem.Lifelong,highlevelexpressionofFcRninAPC
such as dendritic cells (DC),macrophages,and B cells enables the
speciﬁcintracellulartrafﬁckingofIgGandantigen-containingIgG
IC through the endolysosomal system. Importantly, in the case of
thelatter,thismechanismresultsinthedeliveryofcomplexedanti-
gen into compartments in which the local degradative conditions
favorepitopeconservationandtheloadingofimmunostimulatory
antigenic epitopes onto MHC-I and MHC-II. FcRn expression
within APC thus has important immunological consequences for
thegenerationof targetedTcellmediatedimmunityfollowingthe
triggering of a generic cellular entry pathway by the conserved Fc
portion of IgG. Rather uniquely, FcRn-mediated activation of T
cellsinresponsetoIgGICservestointegratethehumoralandcell-
mediated branches of the adaptive immune system and to coor-
dinate the innate immune system, thereby promoting maximal
protective immunity.
ANTIGEN PRESENTATION
MHC CLASS I AND II PEPTIDE LOADING
Functionally,antigen presentation has evolved as a mechanism by
which T cells can monitor the antigenic composition of the body
for the presence of potential pathogens. Given the immense vari-
abilityinantigenstructureandcomposition,thedevelopmentof a
systematizedwayforTcellstorapidlyandefﬁcientlymonitoranti-
genic diversity in their environment can be considered essential
for maximizing organism survival. The major histocompatibility
complex (MHC) molecules, which are expressed at the cell sur-
face in complex with antigenic epitopes, present the T cell with a
conserved recognition structure,the MHC molecule itself,in con-
junction with a unique peptide that transmits information about
the antigenic milieu. Collectively, T cells are thus able to monitor
an immense array of antigensdue to a multitude of clonotypically
expressed T cell receptors (TCR).
The peptide binding characteristics differ among different
classes of MHC molecules. MHC-I molecules, which are rec-
ognized by CD8C T cells, bind peptides of 8–11 amino acids
in length that are generated largely via the process of pro-
teasomal degradation in the cytosol (1). Peptide loading onto
MHC-I occurs in the endoplasmic reticulum (ER) after cyto-
plasmic proteasomal digestion and subsequent peptide import by
the transporter associated with antigen processing (TAP) across
the ER membrane. The vast majority of peptides presented by
MHC-I are thus endogenous to the cell itself (1, 2). In special-
ized cell types, particularly DC, exogenously acquired antigens
can be presented by MHC-I through a process known as cross-
presentation as discussed further below (3). MHC-II molecules,
which educate or activate CD4C T cells in the thymus or periph-
ery, respectively, bind peptides of 10–30 amino acids in length,
which are typically exogenously derived and processed by lyso-
somal proteolysis. While most cells engage in MHC-I presenta-
tion, APCs are proﬁcient at both MHC-I and MHC-II presen-
tation due to the specialized intracellular machinery that they
possess.
PROCESSING PATHWAYS FOR EXOGENOUS ANTIGENS
The generation of peptides suitable for loading onto MHC mole-
cules is dictated at once by the nature of the antigen, the route of
uptake, and additional signals to which the cell is exposed. With
respecttothecontributionof theantigenitself,certainepitopesof
aproteinoftenexhibitimmunodominanceleadingtothepreferen-
tialprocessingandpresentationofsuchepitopesoverothers(4,5).
Manyfactorscontributetothepreferentialselectionofcertainepi-
topes,includingtheactivationstateoftheAPC,therelativeprotein
abundance,theavailabilityandactivityof enzymesresponsiblefor
antigen processing, and previous antigen exposure. Importantly,
immunodominance can have profound implications not only for
shaping the immediate direction of an immune response but also
the nature of future immune response by altering memory T cell
pools (1, 4).
ProcessingofexogenousantigenforloadingontoMHC-IImol-
ecules is initiated upon entry into the early endosome. As the
antigen moves progressively deeper into the endolysosomal sys-
tem,the pH of the vesicles progressively decreases from the mildly
acidic environment of the early endosome to the highly acidic
milieu of the lysosome (6). Degradation of the antigen occurs
largely by the actions of various enzymes, particularly cathepsin
proteasesandtheg-interferon-induciblelysosomalthiolreductase
(GILT),whoseactivityisregulatedbythelocalpH(7).Whilethere
is considerable heterogeneity in the morphology and content of
thevariousendolysosomalcompartmentsandMHC-IImolecules
can be found throughout compartments at various stages of mat-
uration, the majority of evidence indicates that epitope loading
onto MHC-II occurs in the late endosome, which has also been
referred to as an MHC-II compartment, where numerous chap-
erones facilitate this process (8). However,conditions within both
the late endosome and phagosome are thought to be optimal for
the generation of peptides ideal for MHC-II loading and trafﬁck-
ingof suchpeptidesbetweenthesetwocompartmentsisknownto
occur (1,2). Given the dependence of antigenic processing on pH,
the efﬁciency of productive antigen processing varies across cell
types with different endolysosomal pH ranges (6, 9). The highly
acidic environment within macrophages enables the efﬁcient gen-
eration of peptides suitable for loading on MHC-II but results in
the loss of many potentially antigenic epitopes due to the harsh
processing conditions. In contrast, the endosomal pH is much
morestrictlybufferedwithinDCandgenerallyremainsinamuch
more neutral range due to the alkalinizing actions of the NADPH
oxidase NOX2, which is recruited to phagosomal and endoso-
mal membranes (10). Thus,a different set of MHC-II-compatible
peptides emerges from antigen processing in different cell types.
Cross-presentation, the loading of exogenously derived anti-
gens onto MHC-I, is highly cell type-speciﬁc and has so far only
been documented to occur efﬁciently in DC. Given that epitopes
suitable for loading onto MHC-I are more susceptible to degra-
dation than MHC-II-compatible epitopes, the milder processing
conditions within DC are thought to provide the ideal environ-
ment for their generation (10–12). Subsequent to cell uptake by
endocytosis or phagocytosis, exogenous antigens within DC are
exposed to a near neutral endosomal/phagosomal pH resulting
from an incomplete assembly of the vacuolar (V)-ATPase on
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vesicle membranes as well as the Rac2 and Rab27a-dependent
recruitment of NOX2 (10, 11, 13). The generation of reactive
oxygen species (ROS) by NOX2 and subsequent consumption of
protons in the compartment results in a near neutral pH. Addi-
tionally,proteasomal recruitment of lysosomal proteases has been
shown to be lower in DC compared to macrophages (14). Such
mild conditions alone,however,cannot produce peptides suitable
for MHC-I loading and a critical step in cross-presentation is the
retro-translocationof antigenoutof theendosomalcompartment
and into the cytosol where it is processed by the proteasome in a
manner akin to endogenous proteins (15). The precise mecha-
nism for this retro-translocation is not known but the process of
ER-associateddegradation(ERAD)and,speciﬁcally,theactionsof
theSec61retrotransloconhavebeenimplicatedintheprocess(15,
16). The peptides generated by proteasomal processing are then
imported into the ER, where the majority of MHC-I is loaded
with peptide via the actions of TAP (15). Further peptide trim-
ming within the ER is mediated by ER aminopeptidases (ERAPs)
before nascent MHC-I molecules are loaded with the ﬁnal epi-
tope assisted by chaperones such as calnexin and calreticulin (17).
While the involvement of the proteasome and ER machinery in
cross-presentation is well accepted, it has been proposed that the
phagosome or endosome itself may form a self-sufﬁcient cross-
presentation compartment that contains signiﬁcant amounts of
ER-associated proteins (18, 19). These include Sec61, TAP, IRAP
(an N-terminal peptidase very similar to ERAPs), and MHC-I
itself (18–20). It is perhaps most likely that these pathways are
not mutually exclusive and that the speciﬁc route through which
a given antigen is processed depends upon numerous factors.
This raises the important principle that for both MHC-I and
MHC-II antigen processing, there exists a very tight link between
the generation of suitable epitopes for MHC loading and the
environment within the antigen processing compartments. Thus,
regulation of antigen processing is highly susceptible to cellu-
lar and antigen context. Exposure of APC to stimuli such as
TLR ligands, pro- or anti-inﬂammatory cytokines, or hormones
can exert signiﬁcant impact upon the phagolysosomal process-
ing efﬁciency by varying the pH, protease expression, endosomal
maturationprocesses,orsignalingcascadesinitiateduponantigen
internalization (21–25).
RECEPTOR-MEDIATED ANTIGEN UPTAKE
Themeansbywhichanantigenisinternalizedisknowntosigniﬁ-
cantlyimpactitsintracellularhandlingbythecell.Manyreceptors,
particularly PRR, have been identiﬁed that promote antigen pre-
sentation either by increasing the rate of antigen uptake by other
cell surface receptors or by initiating signaling pathways, which
inﬂuence antigen handling once they are internalized. Impor-
tantly, different receptors can exert different effects on MHC-II
and MHC-I antigen presentation and this has been linked to
the routing of antigen to different compartments by the various
receptors. Thus, whereas internalization of an antigen by scav-
enger receptors enhances MHC-II loading and the activation of
CD4C T cells, antigen uptake via the MR promotes MHC-I load-
ingandCD8C Tcellactivation,likelybyenhancingantigenexport
to the cytosol (26–28). In contrast,C-type lectin receptors such as
CLEC9, Dectin-1, and DEC-205 (lymphocyte antigen 75), which
are expressed on macrophages and DC, promotes antigen pre-
sentation via both MHC-I and MHC-II (29–33). Indeed, many
studies have attempted to target antigen to these various receptors
in order to stimulate directed antigen presentation and gener-
ate enhanced antigen-targeted immune responses. The strategy
mostcommonlyemployedintheseexperimentshasbeentoeither
conjugate antigen or to fuse antigen with a receptor-speciﬁc mon-
oclonal antibody (32, 34, 35). Thus, while each of these strategies
has been shown to effectively enhance antigen-speciﬁc immune
responses,itcannotbeexcludedthatsuchresponseswerepartially
mediated by binding of the Fc portion of the targeting antibody
to FcgR,which would also enhance antigen presentation (36–38).
CLASSICAL Fcg RECEPTORS
Cell surface expression of IgG binding receptors is a common fea-
ture of APC that allows them to react with high sensitivity to both
monomeric IgG and antigen-containing IgG IC. The family of
classical FcgR consists of several members with differential bind-
ing afﬁnities and signaling capabilities, which transmit a diverse
rangeofresponsesuponligationandtherebyformahighlytunable
system for the regulation of immune responses.
Broadly, FcgR can be separated into activating and inhibit-
ing receptors, all of which likely arose from a series of gene
deletion/duplication and inter-gene recombination events (39).
In humans, activating receptors include hFcgRI, hFcgRIIA,
hFcgRIIC, hFcgRIIIA, and hFcgRIIIB, whereas in mice these
include mFcgRI, mFcgRIII, and mFcgRIV (37, 38). Activation by
thesereceptorsismediatedbyanimmunoreceptortyrosine-based
activation motif (ITAM) that is located either directly in the cyto-
plasmic tail of the receptor, in the case of FcgRII homologs, or in
thetailoftheFcreceptorcommong-chain(FCER1G),whichasso-
ciates tightly with the cytoplasmic tails of FcgRI, hFcgRIIIA, and
mFcgRIV. Ligand binding induces phosphorylation of the ITAM
motifs by proto-oncogene tyrosine-protein kinase Src (SRC) fam-
ily kinases, which, in turn, trigger the recruitment and docking of
spleen tyrosine kinase (SYK) via its two SRC homology 2 (SH2)
domains.SubsequentautophosphorylationofSYKinitiatesacom-
plexwebofintracellularsignalingpathwaysincludingactivationof
the mitogen-activated protein kinase (MAPK), phosphoinositide
3-kinase (PI-3K), and protein kinase C (PKC) cascades (40–42).
Inhibitory FcgRs include FcgRIIB orthologs in both mouse and
humansystems,whichpossessanimmunoreceptortyrosine-based
inhibitory motif (ITIM) in their cytoplasmic tails. Upon ligand
binding, ITIM phosphorylation induces the recruitment of phos-
phatases such as SHIP-1 [inositol polyphosphate-5-phosphatase
(INPP5D)],whichdrivesubsequentimmunosuppression(37,43).
Numerouspolymorphisms,splicevariants,andcopynumbervari-
ations for FcgR family members have been documented in both
humansandmice,manyofwhichwereshowntoaltereitherligand
binding, downstream signaling or be associated as risk factors for
human disease (44–46).
Importantly,therangeof ligandbindingafﬁnitiesvarieswidely
across FcgR family members. In humans, FcgRI has the highest
afﬁnity for monomeric IgG1,the lowest for monomeric IgG2,and
intermediate afﬁnity for IgG3 and IgG4. Given this high afﬁn-
ity for monomeric IgG, it is widely believed that most FcgRI is
saturated at steady state in the presence of physiological serum
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IgGconcentrations(47).FcgRIIandFcgRIIIvariantsexhibitrela-
tivelypoorbindingformonomericIgGbutamuchhigherbinding
for multimeric IgG, such as is found in IgG IC, due to the ability
of suchmultivalentligandstocrosslinksurfacereceptors.Further-
more, it is increasingly being appreciated that expression of FcgR
varies widely across types of APC. Whereas transcript analysis
hasrevealedthatmonocytes,macrophages,andmonocyte-derived
DC (moDC) from mice express relatively high levels of all FcgR,
expression in DC subsets is considerably lower (38). Both XCR1C
and CD172aC conventional DC (cDC) as well as plasmacytoid
DC (pDC) predominantly express FcgRIIA and FcgRIIB tran-
scriptswithlowerlevelsof expressionof otherFcgR.Indeed,three
groups have recently identiﬁed expression of FcgRI as a highly
sensitive marker for the differentiation of moDC from cDC (48–
52).ThesedifferencesinafﬁnityforIgGof differentsubclassesand
valencies as well as differential distribution of receptor expression
across APC types have important implications for the ﬁne tuning
of immune regulation, as will be discussed below.
Internalization by FcgR has clearly been shown to increase the
ability of APC to present antigen contained within an IgG IC and
thus to stimulate CD4C and CD8C T cell responses (36, 53–57).
FcgR ligation by IgG leads to uptake of bound ligands by either
clathrin-dependentreceptor-mediatedendocytosis,if theligandis
a small IgG IC,or by actin- and PI-3K-dependent phagocytosis,if
the ligand is a large IgG IC (58). FcgR-mediated internalization,
which is dependent on the common g-chain, directs IgG IC into
an intracellular pathway that is conducive to antigen presentation
whilesimultaneouslyinducingmaturationoftheinternalizingDC
(56,59).Importantly,however,FcgRbindingtoIgGoccursatneu-
tral pH such as is found at the cell surface, but not in the acidic
pH range that is found in the endolysosomal system (60). FcgRs
are thus unable to bind their cargo intracellularly and such that
they release it in the acidifying endosomes soon after internaliza-
tion. Given the inability of FcgR to directly route IgG IC through
speciﬁc antigen processing compartments, it was thus unclear for
an extended period of time whether the contribution of FcgR to
enhanced antigen presentation was simply the result of increased
antigenuptake,ofsignalingpathwaysinitiatedbyIgGIC-mediated
FcgR cross-linking or by an unidentiﬁed mechanism.
FcRn: AN INTRACELLULAR IgG BINDING RECEPTOR
The discovery of an intracellular IgG binding receptor distrib-
utedthroughouttheendolysosomalsystemwithinAPCandwhich
exhibits speciﬁc binding only under acidic conditions presented
the possibility that IgG IC could be speciﬁcally trafﬁcked toward
antigen processing compartments subsequent to FcgR-mediated
uptake.
Fc receptor was ﬁrst identiﬁed in the intestinal epithelial cells
of neonatal rodents and thus came to be known as the neonatal
Fc receptor, FcRn (61). Indeed, FcRn remains best known for the
critical role it plays in transcytosis of IgG across intestinal epithe-
lialcellsatmucosalbarrierswhereitservestheimportantfunction
of delivering maternal IgG to neonatal rodents with undeveloped
immune systems (62–64). In the case of humans, such passive
acquisition of IgG in an FcRn-dependent manner occurs antena-
tally via the placenta (65, 66). However, discovery of FcRn in the
hepatocytes of adult rats was indicative that FcRn function was
not limited to the neonatal system and this was later substanti-
ated by the documentation of FcRn expression in adult human
intestinal epithelial cells (64, 67). Indeed, the other well-known
role for FcRn, protecting its serum ligands (IgG and albumin)
from catabolism via recycling, is an important process ongoing
throughout life (68, 69). Lifelong FcRn expression has now been
documentedinawiderangeofparenchymalcellsinvarioustissues
includingintestinalepithelialcells,airwayepithelialcells,placental
syncytiotrophoblasts, hepatocytes, and endothelial cells in species
ranging from humans to rodents to camels (66, 67, 70–72). Crit-
ically, discovery of high level FcRn expression in hematopoietic
cells such as B cells, macrophages, and DC raised the possibility
that FcRn could be directly involved in the presentation of IgG-
complexed antigens to T cells, which themselves do not express
FcRn (73, 74).
Several key features of FcRn biology render it an ideal can-
didate molecule for participation in IgG IC antigen presentation
(Figure1).FcRn,whichisencodedbytheFcgrt gene,isanMHC-I
relatedmoleculethatassociatesdirectlywiththeb2-microglobulin
chain that enables its proper assembly and stability (75). FcRn is
located primarily intracellularly within the endolysosomal system
of APC and less so on the cell surface where it could theoretically
compete for IgG binding with FcgR (76). The critical binding site
for FcRn on the IgG Fc region involves the I253, H310, and H435
residues within the CH2:CH3 domains of IgG Fc and is distinct
from where FcgR binding to IgG occurs (77–84). In contrast to
FcgRs,bindingisentirelyindependentof IgGglycosylation.Thus,
the simultaneous ligation of an IgG molecule by both classes of
receptorwouldbepossible.FcRnbindsIgGwithveryhighafﬁnity
of approximately 10mM in a 2:1 stoichiometric ratio such that
binding of multimeric IgG IC would be expected to result in sig-
niﬁcant cross-linking of FcRn (85–87). Perhaps most importantly
for the purposes of antigen presentation, binding of FcRn to IgG
occurs in the acidic pH range of 4.5–6.5 due to protonation of
the two critical histidine residues under low pH conditions and
the stabilization of the resulting salt bridges with acidic residues
in FcRn by a neighboring isoleucine residue (88, 89). These pHs
correspond to the pH range that is found across various compart-
ments of the endolysosomal system, thereby enabling direct high
afﬁnity binding of FcRn to its ligand throughout the compart-
ments where the processing for antigen presentation is known to
occur (6, 90). Furthermore, FcRn is known to bind and actively
trafﬁc monomeric IgG across polarized epithelial cells and within
endothelial cells, thereby establishing a direct precedent for its
ability to engage in endosomal IgG routing and consistent with
a dileucine motif in its cytoplasmic tail (91–94). FcRn thus pos-
sesses ideal characteristics enabling it to function downstream of
cell surface FcgR in facilitating the processing of IgG-complexed
antigens for presentation on MHC molecules.
FcRn IN MHC-II ANTIGEN PRESENTATION
The ﬁrst indication that FcRn might enhance antigen presenta-
tion on MHC-II came from a study that examined the transfer
of IgG-complexed ovalbumin (OVA) across the intestinal barrier
and the delivery of IgG IC to local DC in the lamina propria
and mesenteric lymph nodes (mLN) (95). Subsequent to oral
administration of ﬂuorescently labeled IgG IC, ﬂuorescent signal
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FIGURE 1 | FcRn within dendritic cells enables the presentation of
IgG-complexed antigens to CD4
+T cells and CD8
+T cells. Following IgG
opsonization of antigens from sources such as microbes or tumors, the
immune complexes (IgG IC) bind to FcgR on the surface of dendritic cells
(DC).This initiates receptor-mediated endocytosis, which delivers the IgG
into the endolysosomal system of compartments. As these vesicles
become more acidic during their maturation due to the recruitment of the
vacuolar ATPase (V-ATPase), IgG IC dissociate from FcgR and bind instead
to FcRn, which enables the subsequent trafﬁcking of the IgG IC into antigen
processing pathways that promote the generation of epitopes compatible
with loading onto MHC class I and MHC class II. Machinery known to be
involved in the presentation of soluble antigens for MHC class I processing
and presentation, such as gp91-phox, Rab27 , Sec61,TAP (transporter
associated with antigen processing), and the proteasome, are all
preferentially recruited to the IgG IC-containing intracellular vesicles upon
ligation of FcRn. Less information is available on the compartments
involved in FcRn-facilitated MHC class II restricted presentation and it
remains unknown whether this occurs within the same intracellular
compartment as MHC class I-restricted processing. Once at the surface,
these peptide loaded MHC molecules are then able to prime CD8
+ and
CD4
+ T cells, respectively. Furthermore, ligation of FcRn by IgG IC induces
the production of IL-12 by the DC.The secreted IL-12 acts upon the primed
CD4
+ T cells to induceTh1 polarization and upon the CD8
+ T cells to
promote activation and cytotoxicity. FcRn within DC thus contributes to the
activation of cell-mediated adaptive immune responses that contribute to
pathogen eradication and tumor protection.
was detected in cells of the intestinal lamina propria and CD11cC
cellsofthemLNinmiceexpressingahumanFcRntransgene(hFC-
GRT/hB2M/mFcgrt / ) but not in mice deﬁcient in expression of
FcRn (Fcgrt / ). This result clearly indicated that efﬁcient uptake
of IgGICbymucosalDCoccurspreferentiallyinFcRn-expressing
mice and is consistent with the demonstration that FcRn on neu-
trophils increases the rate of phagocytosis of IgG IC (96). Cocul-
tureofOVA-speciﬁcCD4C TcellswithCD11cC cellsisolatedfrom
the mLN of mice fed OVA IgG IC induced T cell activation only
if the mice expressed FcRn. These data strongly indicated that DC
werecapableof activatingTcellsinresponsetoIgGICbutdidnot
conclusively show that FcRn’s locus of action was in the DC since
drastically less IgG IC would reach DC in Fcgrt /  animals given
the inability of FcRn-deﬁcient epithelium to transcytose lumenal
IgG IC. Similarly, the demonstration that FcRn contributes to
protection from the intestinal pathogen Citrobacter rodentium in
the presence of speciﬁc IgG and that proliferation of C. roden-
tium-speciﬁc CD4C T cells in the mLN was only observed in mice
expressing an epithelial-speciﬁc FcRn transgene cannot be said to
indicate a direct role for FcRn in antigen presentation (97). Thus,
while these studies elegantly demonstrated the role of FcRn in
delivering lumenal IgG IC to the mucosal immune system and
thereby enabling monitoring of its contents, they do not conclu-
sively demonstrate a role for FcRn in the direct presentation of
antigen by APC.
ConclusiveevidencesupportingadirectroleforFcRninmedi-
ating MHC-II antigen presentation was achieved in a study that
was the ﬁrst to document that FcRn responds differentially to
monomericIgGandmultimericIgGIC.WhereasmonomericIgG
is protected in the circulation by FcRn in both hematopoietic
and parenchymal cells, leading to profound hypogammaglobu-
linemia in Fcgrt /  animals, multimeric IgG IC are much more
rapidly cleared from the circulation of wild type (WT) mice than
monomeric IgG (69,76,98). Importantly,bone marrow chimeras
inwhichWTmicewerereconstitutedwithbonemarrowcellsfrom
either WT or Fcgrt /  animals clearly indicated that hematopoi-
etic cells were responsible for the rapid loss of IgG IC from cir-
culation. This ﬁnding suggested that IgG IC were being degraded
within hematopoietic cells, a process that might lead to the gen-
eration of epitopes for loading onto MHC molecules. Indeed,DC
isolated from WT mice were able to efﬁciently prime CD4C T
cells when they had been pre-incubated with IgG IC formed in
the presence of as little as 0.05mg/ml of OVA antigen. DC isolated
from Fcgrt /  animals, in contrast, required antigen concentra-
tions nearly 1000-fold higher in order to induce equivalent CD4C
T cell activation, indicating that FcRn greatly enhances the ability
of DC to generate MHC-II compatible epitopes from IgG IC-
delivered antigens. These results were conﬁrmed with the use of
IHH-IgG, a chimeric antibody molecule engineered to have ala-
ninesubstitutionsinthreeFc-domainresiduescriticalforbinding
to FcRn (I253A, H310A, and H435A) and thereby unable to bind
to FcRn while retaining FcgR binding afﬁnity (99). WT DC incu-
bated with IHH-IgG IC failed to induce efﬁcient CD4C T cell
proliferation compared to those incubated with the non-mutated
parental IgG. Confocal microscopy on human moDC loaded with
ﬂuorescently labeled IgG IC revealed strong colocalization with
FcRn within 5min of IgG IC exposure. Furthermore,whereas IgG
IC were directed into a LAMP1C compartment within 30min,
IHH-IgG IC did not co-localize with LAMP1 and instead seemed
to disappear from the cell entirely in this time frame. Given that
LAMP1isawell-knownlysosomalmarker,thesedataindicatethat
FcRn functions to direct IgG IC into lysosomes, which is a com-
partment in which MHC-II compatible epitopes are known to be
efﬁciently generated (1). Together, these ﬁndings ﬁrmly establish
thatFcRninDCcontributesdirectlytoactivationof CD4C Tcells
viaamechanisminvolvingdegradationof IgG-complexedantigen
in a manner, which generates epitopes compatible with MHC-II
loading.
Details of the mechanism by which FcRn promotes MHC-II
antigen presentation have not yet been fully elucidated; how-
ever, several studies have identiﬁed important components of the
process. Whereas FcRn enhanced antigen presentation in both
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bone marrow-derived macrophages (BMMC) and dendritic cells
(BMDC) following FcRn-mediated endocytosis, this effect was
lost in BMDC, but not BMMC, when the antigen was taken up
via phagocytosis (100). This was shown to be due to the failure
of phagocytosing BMDC to adequately acidify their phagosomes
subsequent to IgG IC internalization, which is a known charac-
teristic of DC but is non-permissive for FcRn–IgG binding (1,
101). In contrast, BMMC efﬁciently acidiﬁed both phagosomes
and endosomes thereby promoting binding of FcRn to its IgG
IC ligand. Sufﬁcient acidiﬁcation of the endocytic environment
is thus a key factor for FcRn-mediated MHC-II antigen presenta-
tion. Interestingly, FcRn has been found to interact directly with
the invariant chain (CD74) that is critical for assembly and traf-
ﬁcking of MHC-II molecules and is upregulated by inﬂammatory
stimuli(1,102).Infact,trafﬁckingof FcRnintothelateendosome
and lysosome of epithelial cells,macrophages,and DC was shown
to beentirely dependent uponits co-expression withthe invariant
chain.Incontrast,thecytoplasmictailof FcRnitself playedalmost
no role in determining FcRn localization throughout these com-
partments since reconstitution of cells with a tailless FcRn mutant
had little impact on its endolysosomal distribution as long as the
invariant chain was also present in the cells. The relevant residues
for mediating FcRn trafﬁcking were found to be two dileucine-
based motifs located in the endosomal sorting signal cytoplasmic
tailoftheinvariantchain(103).TheinteractionbetweenFcRnand
the invariant chain was initiated in the ER and persisted through-
out the endosomal system. It thus appears that FcRn shares a very
similar intracellular sorting route to MHC-II whose endolysoso-
mal distribution has also been shown to depend on its association
withtheinvariantchain(104,105).Thisisparticularlyinteresting,
given the recent ﬁndings that phagosomes behave autonomously
in terms of cargo degradation and MHC-II antigen presentation
and that the resulting CD4C T cell activation was signiﬁcantly
accelerated when antigen was delivered in the form of an IgG
IC (106). Thus, the tight overlap between the trafﬁcking of the
two molecules places FcRn in an ideal position to deliver IgG-
complexedantigensforloadingontoproximalMHC-IImolecules
subsequent to their processing by lysosomal proteases.
FcRn IN MHC-I ANTIGEN CROSS-PRESENTATION
Conclusive evidence that FcRn in DC contributes to CD4C T
cell activation in response to IgG-complexed antigens raised
the likelihood that it might also mechanistically contribute to
the cross-presentation of antigens in IgG IC. Numerous studies
demonstratingthatIgGICefﬁcientlydeliverantigensintoacross-
presentation pathway strongly supported this hypothesis (56, 59,
107). Importantly, each of these studies identiﬁed FcgR as being
critical for initiating cross-presentation and, while endosome-to-
cytosol transport (59), proteasomal processing, and TAP1–TAP2
transport (56) were identiﬁed as important for FcgR-dependent
antigen processing, the intracellular routing of the IgG IC itself
was not investigated.
In contrast to MHC-II antigen presentation, which is car-
ried out by most types of APC, cross-presentation occurs selec-
tively within DC. Speciﬁcally, the majority of literature on cross-
presentation has identiﬁed the CD8C DC subset in mice, or their
human BDCA-3C DC counterparts, as being by far the most
competent cross-presenters compared to even other DC subsets
(108–110). Mechanistically, this has been explained by their non-
monocytic lineage, which confers a distinctly neutral endosomal
pH enabling preservation of antigenic integrity for the genera-
tion of intact epitopes conducive to MHC-I loading (6, 10, 11,
101). A caveat to these ﬁndings on the competency of DC sub-
sets for cross-presentation is that most studies have examined the
processof cross-presentationasitpertainstosolubleproteinanti-
gen. The one study having examined cross-presentation of IgG
IC by different DC subsets reported that CD8  DC were capa-
ble of cross-presenting IgG IC at a similar magnitude to their
CD8C counterparts but that there was an absolute requirement
for expression of functional FcgR only on the CD8  DC (107).
Initial studies of the ability of FcRn to mediate cross-
presentation of IgG-complexed antigen were carried out in
CD8CCD11b  and CD8 CD11bC DC over a wide range of anti-
gen concentrations. Whereas cross-presentation of antigen deliv-
ered as an IgG IC was not affected by FcRn in CD8CCD11b  DC,
cross-presentation of IgG-complexed antigens by CD8 CD11bC
DC was signiﬁcantly impaired in the absence of FcRn (60).
CD8 CD11bC DC expressing FcRn were able to activate a robust
CD8C T cell response when exposed to antigen concentrations
100-fold lower than DC from Fcgrt /  mice. Similar results were
seenwhenCD8 CD11bC DCwereexposedtoIHH-IgGIC,which
were no more effective at priming CD8C T cells than soluble
antigen. Importantly, whereas CD8CCD11b  DC were found to
activate CD8C T cells in response to the cross-presentation of
5–10mg/ml soluble antigen, as reported in the literature, FcRn
enabled CD8 CD11bC DC to stimulate similar magnitudes of
CD8C T cell activation in response to as little as 0.5mg/ml of IgG-
complexed antigen (10, 11, 60, 101, 111). In fact, at high antigen
concentrations or following prolonged incubation times where
soluble uptake of antigen is efﬁcient, FcRn was not observed to
promote cross-presentation (100). Consistent with initial stud-
ies showing the importance of FcgR for cross-presentation of
IgG IC, FcgR were found to be critical for FcRn-mediated cross-
presentation by enabling the initial cell surface binding of IgG
IC and facilitating internalization of the complexes into FcRn-
containing endosomes or phagosomes. The physiological rele-
vance of this process was established by subsequent in vivo studies
demonstrating the importance of FcRn in establishing system-
wide immunity resulting from cross-priming and conferring pro-
tection from colorectal cancer (CRC) (112, 113). These data pro-
vided conclusive evidence that FcRn enables cross-presentation
of IgG-complexed antigens downstream of FcgR and that this is
a physiologically meaningful process, which is active in initiating
immune responses to low doses of antigen in the early stages of
infection.
The differential ability of FcRn to enable cross-presentation
in CD8 CD11bC versus CD8CCD11b  DC was found to reﬂect
the known biology of these two DC subsets. Given that the IgG–
FcRn interaction requires an acidic pH, the neutral pH that
is present in endocytic compartments of CD8CCD11b  DC is
not conducive to strong ligand receptor interaction. In contrast,
the intermediate endosomal acidity level of CD8 CD11bC DC
between that of macrophages and CD8CCD11b  DC provides an
ideal binding environment for FcRn binding to IgG IC (6,9). The
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importance of acidiﬁcation to FcRn-mediated cross-presentation
was shown by its inhibition in the presence of vacuolar ATPase
(V-ATPase) inhibitors and by the active enrichment of V-ATPase
on the phagosomal membranes of compartments in which FcRn
was crosslinked by IgG IC but not on those containing IHH-IgG
IC (60). Nonetheless, the process by which FcRn enables cross-
presentation employs much of the same molecular machinery
as does the cross-presentation of soluble antigen by CD8C DC.
Speciﬁcally,FcRnligationbyIgGICledtotheselectiveenrichment
of the NOX2 component gp91-phox, the Sec61 retrotranslocator,
theTAPtransporter,andtheRab27aGTPasetophagosomalmem-
branes. Furthermore,FcRn-mediated cross-presentation required
cytosolic export of antigen and proteasomal processing. In addi-
tion to directing IgG IC toward specialized antigen processing
mechanisms, which lead to the surface presentation of epitope-
loaded MHC-I, cross-linking of FcRn by IgG IC induced a sig-
naling cascade,resulting in enhanced secretion of the cytotoxicity
promotingcytokineIL-12,therebyprovidinganadditionalstimu-
lus to encourage activation of antigen-primed and speciﬁc CD8C
T cells (113). FcRn within CD8 CD11bC DC thereby enables
cross-presentation of antigen within IgG IC via multiple mech-
anisms. Among others, these include trafﬁcking of complexed
antigen into a processing pathway that promotes epitope conser-
vation but which is not the default pathway for soluble antigens in
CD8  DC.
Identiﬁcation of FcRn as a necessary facilitator for IgG IC
cross-presentation provides an important intracellular mecha-
nistic explanation for numerous demonstrations of the ability
of IgG IC to activate CD8C T cells. Similarly, existing studies
not having directly examined FcRn but having looked at IgG
IC-mediated cross-presentation can provide valuable informa-
tion about additional processes that are likely to be involved
in FcRn-mediated cross-presentation. The existence of an anti-
gen storage compartment that persists for a prolonged period
of time within IgG IC-loaded CD8  DC is not only consistent
with the slower phagosome-to-cytosol release kinetics observed
for FcRn-mediated antigen presentation but also suggests that the
stable binding of FcRn to IgG IC in the acidic endolysosomal
environment might contribute to creating a durable reservoir of
immunostimulatory antigen (60, 114). With respect to additional
DC subsets,pDC,which cross-present soluble antigen poorly,dis-
play signiﬁcantly enhanced cross-presentation when antigens are
targeted to the surface FcgR in the form of IgG IC (22, 115).
Given the dependence of IgG IC cross-presentation on intracellu-
lar processing downstream of FcgR-mediated uptake,this ﬁnding
predicts a role for FcRn in the cross-presentation of IgG IC by
pDC. Furthermore, studies on human DC subsets have demon-
strated enhanced cross-presentation when antigen is delivered in
the form of an IgG complex, thus, indicating that FcRn’s abil-
ity to enhance CD8C T cell activation via cross-priming extends
to human DC (22, 116). Direct proof of FcRn’s ability to enhance
MHC-IdrivenactivationofCD8C TcellsandMHC-IIdrivenacti-
vation of CD4C T cells in humans will have signiﬁcant therapeu-
tic implications based on the number of physiological processes
shown experimentally to be regulated by FcRn-mediated antigen
presentation.
PHYSIOLOGICAL SIGNIFICANCE OF FcRn-MEDIATED ANTIGEN
PRESENTATION
Fc receptor-mediated antigen presentation plays a signiﬁcant role
in the regulation of physiological processes that contribute to
health and disease. Indeed, an important positive feedback loop
exists between FcRn-mediated MHC-II antigen presentation and
the production of IgG by B cells. Targeting antigen to DC is a
known mechanism to induce CD4C T cell help, which is essential
for antibody responses (117). This process of driving T cell help
for promoting humoral immunity has been shown to be further
accelerated when antigen is delivered to DC in the form of an IgG
IC, which stimulates FcgR-mediated antigen uptake (118). That
thisprocessisdependentonFcRn-mediatedprocessingof theIgG
IC itself has been shown in a series of studies using an animal
model in which the bovine FcRn (bFcRn) has been overexpressed
in transgenic mice (119,120). Immunization of bFcRn transgenic
mice,evenusingweaklyimmunogenicantigens,ledtosigniﬁcantly
greaterexpansionof antigen-speciﬁcBcellsandplasmacellscom-
pared to immunization of WT mice, a ﬁnding that is consistent
with the binding of bFcRn to mouse IgG (119–122). Importantly,
not only was production of antigen-targeted antibody increased
in bFcRn overexpressing mice but signiﬁcantly greater diversity in
the antibody repertoire was seen following immunization (119).
Given that increased antigen-speciﬁc antibody production can be
expected to lead to greater amounts of antigen presentation by
FcRn and thus feed back to even greater antibody synthesis, these
results demonstrate that FcRn contributes to shaping the produc-
tion and diversity of its own ligand and thus serves an important
role in both cellular and humoral immunity.
The end result of FcRn-mediated antigen presentation is often
apowerfulpro-inﬂammatoryresponsewhichcanbeeitherhelpful
or harmful depending on the context. Opsonization of infectious
agentsisacriticalparameterintheeradicationof manypathogens
and, while protection is partially attributable to antibody depen-
dent cellular cytotoxicity (ADCC), evidence indicates that FcRn-
mediated antigen presentation also plays a signiﬁcant role. FcRn
hasbeendirectlyimplicatedinprotectionfromintestinalC.roden-
tium infectioninamodelinwhichCD4C TcellactivationandIgG
arecriticalparametersinsuccessfulpathogenclearance(97).Addi-
tionally,FcRn contributes to CD4C and CD8C T cell activation in
response to vaccination with IgG opsonized and inactivated Fran-
cisella tularensis (123, 124). Upon rechallenge with F. tularensis,
mice having been vaccinated with the opsonized microbes were
signiﬁcantly more protected from this intracellular pathogen than
microbealonecontrols.FcRn-mediatedprotectionfrominfection
in response to IgG-complexed microbial antigens is not only lim-
itedtobacterialpathogensbutalsoextendstoviralinfectionssuch
as inﬂuenza, herpes simplex, and HIV model viruses (125–127).
Importantly, FcRn-mediated protection induced by vaccination
against these viruses was shown to result in the generation of
long-term memory T cell responses,thereby conﬁrming a mecha-
nistic role for antigen presentation in the process (126). Critically,
this body of work has ﬁrmly established that T cell-mediated
protection against microbial and viral antigens that is initiated
by IgG-complexed antigen, depends upon the antigen presenta-
tion function of FcRn within DC. Thus, FcRn-mediated antigen
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presentation provides an intracellular mechanism that explains
the ﬁndings of many other studies documenting IgG IC-driven
protectionfrominfection.Amongotherpathogens,targetinganti-
gen in the form of IgG IC toward FcgR has been shown to be
effective against human papilloma virus (HPV) and Salmonella
typhimurium via a mechanism which is most likely also depen-
dent upon FcRn following initial IgG IC uptake (128–131). The
antigen presentation function of FcRn in the context of invasive
pathogens is thus highly beneﬁcial to the host, particularly since
its high sensitivity enables early immunological activation upon
infection.
The exquisite sensitivity of FcRn to enable the presentation of
small doses of antigen renders it a highly potent immunostim-
ulatory molecule. While this is advantageous in the context of a
foreign pathogen, FcRn-mediated antigen presentation can serve
to promote pathological inﬂammation in the context of autoim-
mune or allergic diseases. Antibody-enhanced cross-presentation
of self-antigensexpressedbypancreaticbcellscandrivethedevel-
opmentof CD8C Tcell-mediatedautoimmunediabetesbybreak-
ing tolerance to endogenous molecules (132). Similarly, antigen
uptake by FcgR in DC has been shown to contribute to allergic
airway hyper-responsiveness and inﬂammation by driving CD4C
T cell activation via a mechanism that almost certainly involves
FcRn (133). Indeed, two additional studies have demonstrated a
direct effect for FcRn in the regulation of allergic airway inﬂam-
mation although they did not identify the cell compartment in
which FcRn was acting (134, 135). Perhaps the most conclusive
evidence for the ability of FcRn-mediated antigen presentation to
promoteinﬂammationcomesfromstudiesconductedintheintes-
tine where FcRn has been shown to drive colitis in the presence of
anti-microbialIgGagainstthecommonmicrobialﬂagellinprotein
(136). Whereas WT mice with high titers of anti-ﬂagellin IgG due
to immunization with this ligand developed severe colitis upon
intestinal epithelial barrier breakage by dextran sodium sulfate
(DSS), Fcgrt /  mice were largely protected from severe weight
loss and tissue damage in this model. Reciprocal bone marrow
chimeras in which serum IgG levels were normalized across all
experimental groups not only demonstrated that protection from
intestinal damage was not due to lower anti-ﬂagellin IgG titers
in Fcgrt /  animals but also identiﬁed the hematopoietic com-
partment as the source of FcRn-mediated inﬂammation. Further
study revealed that CD8 CD11bC DC from the intestines of WT
colitic mice induced far greater CD8C T cell activation in vitro
and in vivo compared to DC from Fcgrt /  mice, directly indi-
cating the importance of FcRn in driving pro-inﬂammatory T cell
responses (60). In spite of the extensive tissue damage that results
from FcRn-mediated intestinal inﬂammation, however,WT mice
aresigniﬁcantlyprotectedfromthedevelopmentofinﬂammation-
associated CRC in comparison to their Fcgrt /  littermates in
whom the protection from FcRn-mediated inﬂammation trans-
latedintodampenedanti-cancerimmunity(113).Consistentwith
the widely recognized importance of CD8C T cells in conferring
anti-tumorimmunity,depletionstudiesinconjunctionwithaDC-
speciﬁc deletion of FcRn conclusively identiﬁed FcRn-mediated
cross-presentation as the mechanism by which tumor protection
was enabled (98, 113). While numerous studies had previously
shown that vaccination strategies utilizing IgG-complexed tumor
antigens were far superior in driving tumor-protective immunity
compared to soluble tumor antigen, this was the ﬁrst demon-
stration that FcRn in DC is an active and important part of the
endogenous anti-tumor immunosurveillance system (137).
LINGERING QUESTIONS IN FcRn-MEDIATED ANTIGEN
PRESENTATION
An important physiological role for FcRn-mediated antigen pre-
sentation has been conclusively demonstrated and many of the
keyintracellularprocessesinvolvedhavebeenidentiﬁed.Nonethe-
less, many valuable questions remain unanswered. How is FcRn-
mediated antigen presentation affected by additional stimuli such
as temporally or spatially proximal TLR-ligation within the IgG
IC-containing DC or the presence of mixed immune complexes
containing immunoglobulins of different subclasses of IgG or
immunoglobulin isotypes (138, 139)? How much impact do
characteristics of the IgG IC, such as ligand composition, IgG-
to-antigen ratios, and IgG IC size, have upon the immunologi-
cal outcome of FcRn-mediated antigen presentation (140–143)?
Are FcRn-trafﬁcked IgG-complexed antigen processed within the
same intracellular compartment for MHC-I and MHC-II load-
ing or are IgG IC routed to distinct endocytic compartments for
each of these processes (106, 144–146)? How is FcRn trafﬁcked
in different subsets or types of APCs and how does this relate to
theaforementionedquestions?Addressingtheseandotherqueries
has important implications for the development of FcRn-targeted
therapeutics that could theoretically be tailored to trigger CD4C
T cells for an extracellular bacterial infection or CD8C T cells for
tumoreradication.Ourincreasingunderstandingofthestructural
details of the FcRn–IgG interaction open signiﬁcant possibilities
for therapeutic development (80, 87) that can best be applied
and exploited by developing a complete understanding of the
mechanisms that govern FcRn-mediated antigen presentation.
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